Twist Bioscience
TWST
$91.03
-8.91%
Twist Bioscience is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology, enabling faster, more affordable, and scalable production of high-quality synthetic DNA. The company is a market leader in silicon-based DNA synthesis, leveraging a proprietary semiconductor manufacturing process that overcomes the inefficiencies of traditional plastic-plate methods. The current investor narrative centers on the company's accelerating revenue growth trajectory, driven by strong demand for its NGS tools and antibody discovery services, alongside a path toward profitability as operating losses narrow. Recent attention has been fueled by the stock's inclusion in ARK Invest's portfolio, highlighting its potential as a high-growth disruptive technology play.…
TWST
Twist Bioscience
$91.03
Related headlines
Investment Opinion: Should I buy TWST Today?
Rating: Buy. Twist Bioscience offers a rare combination of accelerating revenue growth (16.9% YoY), improving margins (gross margin 52.0%), and a strong balance sheet (current ratio 3.64) at a historically low PS multiple (trailing 4.47x). The analyst consensus is bullish with all 8 analysts rating it Buy/Outperform, and the average revenue estimate of $846.7M implies 18% growth from trailing twelve months.
Supporting evidence: (1) Revenue growth accelerated from 9.0% to 16.9% in the most recent quarter, driven by NGS Tools and Antibody Discovery. (2) Gross margin improved to 52.0% from 49.6% a year ago, reflecting better product mix and cost controls. (3) Operating margin narrowed from -44.8% to -31.7%, showing operating leverage. (4) The trailing PS of 4.47x is near the bottom of its historical range (14.2x to 193.3x), suggesting the stock is undervalued relative to its own history. (5) Free cash flow burn of -$34.8M is manageable given $151M cash.
Risks & Conditions: The biggest risks are (1) failure to sustain revenue acceleration above 15%, (2) inability to achieve positive free cash flow within 2 years, and (3) macro-driven multiple compression due to high beta (2.115). This Buy rating would be downgraded to Hold if revenue growth decelerates below 10% or if gross margins fall below 48%. It would be upgraded further if the company achieves positive operating income. Overall, Twist Bioscience appears undervalued relative to its growth trajectory and historical valuation, making it an attractive buy for growth-oriented investors.
Sign up to view all
TWST 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Twist Bioscience's accelerating revenue growth, improving margins, and historically low PS multiple create a favorable risk/reward. The key risk is execution—the company must sustain growth and demonstrate a path to profitability. The base case of 15-18% growth and gradual margin improvement is most likely, supporting a target range of $100-$120. A bullish stance would be upgraded to high confidence if the company achieves positive operating income, while a downgrade to neutral would occur if growth decelerates below 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Twist Bioscience's 12-month outlook, with a consensus price target around $118.34 and implied upside of +30.0% versus the current price.
Average Target
$118.34
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$73 - $118
Analyst target range
The stock is covered by 8 analysts, with a consensus leaning bullish. All recent ratings from Guggenheim, Barclays, Evercore ISI, TD Cowen, and Baird are Buy or Outperform equivalents, with no downgrades in the past year. The average estimated EPS for the next fiscal year is $1.16, implying a forward PE of approximately 85x (based on current price), which is not meaningful given current losses. The average revenue estimate is $846.7 million, suggesting 18% growth from the trailing twelve months. The consensus target price is not explicitly provided, but based on the bullish sentiment and recent price action, the implied upside is likely positive. The high target of $1.17 EPS and $855.9 million revenue assumes continued strong growth and margin expansion, while the low target of $1.13 EPS and $831.7 million revenue reflects a more conservative scenario. The narrow range of estimates (EPS spread of $0.04, revenue spread of $24.2 million) indicates high analyst conviction in the near-term outlook. The lack of any downgrades and consistent Overweight/Buy ratings reinforce a positive sentiment, suggesting analysts see a favorable risk/reward for this high-growth synthetic biology company.
Bulls vs Bears: TWST Investment Factors
Twist Bioscience presents a compelling growth story with accelerating revenue, improving margins, and a strong balance sheet, supported by a bullish analyst consensus. However, the company remains unprofitable with negative free cash flow, and its elevated valuation (trailing PS 4.47x) leaves little room for error. The single most important tension is whether the company can sustain its revenue acceleration and achieve operating leverage to reach profitability before growth decelerates. Currently, the bull case has stronger evidence given the improving fundamentals and low historical PS multiple, but the high short interest and macro sensitivity (beta 2.115) warrant caution.
Bullish
- Accelerating Revenue Growth: Revenue grew 16.9% YoY to $103.7M in Q1 FY2026, accelerating from 9.0% in Q4 FY2025 and 7.1% in Q3 FY2025, driven by strong demand in NGS Tools ($52.6M) and Antibody Discovery ($51.1M). This sustained acceleration signals increasing market adoption and commercial momentum.
- Improving Profitability Metrics: Gross margin improved to 52.0% from 49.6% a year ago, and operating margin narrowed from -44.8% to -31.7%, reflecting better cost management and product mix. Net loss shrank to -$30.5M from -$39.3M in Q2 FY2025, demonstrating a clear path toward breakeven.
- Strong Balance Sheet with Low Debt: Current ratio of 3.64 and debt-to-equity of 0.29 indicate ample liquidity and minimal financial risk. Cash of $151.0M provides a runway to fund operations without immediate need for dilutive financing.
- Bullish Analyst Consensus: All 8 analysts rate the stock Buy or Outperform, with no downgrades in the past year. The narrow range of EPS estimates ($1.13-$1.17) and revenue estimates ($831.7M-$855.9M) reflects high analyst conviction in the near-term outlook.
Bearish
- Unprofitable Operations: Despite improving margins, net margin remains deeply negative at -29.4% and free cash flow was -$34.8M in the quarter. The company has yet to demonstrate a clear timeline to GAAP profitability, which could weigh on valuation if growth decelerates.
- Elevated Valuation Multiples: Trailing PS ratio of 4.47x, while low historically, is still a premium to many peers. Forward PS of ~1.99x implies aggressive growth expectations; any miss could lead to multiple compression. Beta of 2.115 amplifies downside risk in market downturns.
- High Short Interest: Short ratio of 9.72 days to cover indicates significant bearish sentiment. While this can fuel a short squeeze, it also reflects skepticism about the company's ability to sustain its growth trajectory and reach profitability.
- Revenue Concentration Risk: The business is heavily reliant on two segments—NGS Tools and Antibody Discovery—which together account for nearly all revenue. Any disruption in either market (e.g., competitive pressure, regulatory changes) could materially impact growth.
TWST Technical Analysis
TWST is in a powerful sustained uptrend, with the stock surging 163.4% over the past year and currently trading at 94.1% of its 52-week range (current price $99.24 vs. 52-week high of $105.47). This positioning near the highs reflects strong bullish momentum and investor optimism, though it also suggests the stock may be overextended in the short term. The 1-year relative strength versus SPY is an impressive 144.3%, confirming the stock's outperformance. Short-term momentum is accelerating sharply, with the 1-month price change of +41.5% and 3-month change of +97.6%, both significantly outpacing the S&P 500's respective returns of -1.25% and +13.6%. This acceleration aligns with the longer-term uptrend, indicating no divergence; however, the rapid pace of gains raises the risk of a mean-reverting pullback. The 1-month relative strength of +42.7% underscores the stock's recent dominance. The 52-week high of $105.47 serves as immediate resistance, while the 52-week low of $23.30 provides a distant support level. A breakout above $105.47 would signal a continuation of the uptrend, potentially targeting new highs, while a breakdown below the recent consolidation area near $85 could indicate a trend reversal. With a beta of 2.115, TWST is more than twice as volatile as the S&P 500, meaning it amplifies market moves and requires careful position sizing.
Beta
2.12
2.12x market volatility
Max Drawdown
-38.2%
Largest decline past year
52-Week Range
$23-$105
Price range past year
Annual Return
+155.8%
Cumulative gain past year
| Period | TWST Return | S&P 500 |
|---|---|---|
| 1m | +31.5% | +1.4% |
| 3m | +77.9% | +10.6% |
| 6m | +162.0% | +8.4% |
| 1y | +155.8% | +20.5% |
| ytd | +181.0% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TWST Fundamental Analysis
Revenue growth is accelerating, with the most recent quarter (Q1 FY2026, ended Dec 2025) reporting revenue of $103.7 million, up 16.9% year-over-year from $88.7 million in the prior-year quarter. This marks a notable acceleration from the previous quarter's 9.0% YoY growth (Q4 FY2025: $99.0 million) and from the 7.1% growth in Q3 FY2025. The growth is driven by two key segments: NGS Tools ($52.6 million) and Antibody Discovery ($51.1 million), both showing robust demand. The revenue trajectory supports the investment case for a company scaling its commercial operations and gaining market share in synthetic biology. The company remains unprofitable, with a net loss of -$30.5 million in the most recent quarter, though this loss narrowed from -$39.3 million in Q2 FY2025. Gross margin improved to 52.0% from 49.6% in the prior-year quarter, reflecting better cost management and product mix. Operating margin was -31.7%, an improvement from -44.8% a year ago, indicating progress toward operating leverage. However, net margin remains deeply negative at -29.4%, typical for a high-growth biotech company still investing heavily in R&D and sales. The balance sheet is healthy, with a current ratio of 3.64 and a low debt-to-equity ratio of 0.29, indicating ample liquidity and minimal financial risk. Free cash flow was -$34.8 million in the quarter, but the company has $151.0 million in cash, providing a runway to fund operations. ROE is negative at -16.4%, reflecting the net loss, but the company's strong cash position and low leverage suggest it can sustain its growth investments without immediate financing pressure.
Quarterly Revenue
$103698000.0B
2025-12
Revenue YoY Growth
+0.16%
YoY Comparison
Gross Margin
+0.52%
Latest Quarter
Free Cash Flow
$-86724000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TWST Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 4.47x, while the forward PS ratio (based on estimated revenue of $846.7 million) is approximately 1.99x, implying the market expects significant revenue growth. The large gap between trailing and forward PS suggests investors are pricing in aggressive top-line expansion. Compared to the industry average (not provided, but typical for medical diagnostics & research), TWST's PS ratio of 4.47x may appear elevated; however, given its revenue growth rate of ~17% and leadership in synthetic biology, a premium is justified. The company's gross margin of 50.7% and improving operating margins support a higher multiple relative to peers with lower growth or margins. Historically, TWST's PS ratio has ranged from as low as 14.2x (Q2 FY2023) to as high as 193.3x (Q2 FY2021). The current trailing PS of 4.47x is near the bottom of its historical range, suggesting the stock is relatively cheap compared to its own past, even after the recent rally. This low PS multiple reflects the market's prior pessimism about profitability, but the improving growth trajectory could drive multiple expansion if the company continues to execute.
PE
-21.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -41x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-31.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Twist Bioscience remains unprofitable with a net loss of -$30.5M in Q1 FY2026 and negative free cash flow of -$34.8M. While the balance sheet is healthy (current ratio 3.64, debt-to-equity 0.29), the company's cash burn rate of ~$35M per quarter implies a runway of about 4 quarters before needing additional capital. Revenue concentration in NGS Tools and Antibody Discovery (combined >99% of revenue) exposes the company to segment-specific downturns. The operating margin of -31.7%, though improving, indicates that fixed costs remain high relative to revenue, and any slowdown in growth could delay the path to profitability.
Market & Competitive Risks: The stock's beta of 2.115 makes it highly sensitive to market movements, and its trailing PS of 4.47x, while low historically, is still a premium to many diagnostic peers. The synthetic biology space is competitive, with players like Ginkgo Bioworks and Codex DNA, and rapid technological change could erode Twist's silicon-based advantage. Regulatory risks in healthcare and biotech, particularly around gene editing and synthetic DNA, could impose compliance costs or limit market access. The recent ARK Invest inclusion highlights the stock's speculative nature, which could lead to sharp sell-offs if sentiment shifts.
Worst-Case Scenario: A combination of revenue growth deceleration (e.g., below 10% YoY), failure to narrow losses, and a broad market sell-off could drive the stock to its 52-week low of $23.30, representing a -76.5% decline from the current price of $99.24. This scenario would likely involve analyst downgrades, a loss of investor confidence, and potential liquidity concerns if cash burn accelerates. The historical max drawdown of -38.24% provides a more moderate downside reference, but given the stock's volatility and high short interest, a -76.5% drop to the 52-week low is a realistic worst-case.
FAQ
The key risks are: (1) Financial risk: The company is unprofitable with negative free cash flow (-$34.8M quarterly), and while cash of $151M provides runway, sustained losses could require dilutive financing. (2) Valuation risk: Despite low historical PS, the stock's beta of 2.115 makes it vulnerable to market downturns, and any growth deceleration could lead to multiple compression. (3) Competitive risk: The synthetic biology space is competitive, and technological disruption could erode Twist's silicon-based advantage. (4) Company-specific risk: Revenue is concentrated in NGS Tools and Antibody Discovery; a downturn in either segment would materially impact growth. The most severe risk is a growth deceleration below 10%, which could trigger a -76.5% decline to the 52-week low of $23.30.
The 12-month forecast is based on three scenarios: Bull case (30% probability) with revenue growth accelerating to 25%+ and positive operating income, targeting $120-$140. Base case (50% probability) with 15-18% growth and gradual margin improvement, targeting $100-$120. Bear case (20% probability) with growth decelerating below 10% and margin deterioration, targeting $60-$80. The base case is most likely, supported by the current revenue trajectory and analyst estimates. The AI assessment is bullish with medium confidence, citing accelerating growth and low historical PS. Key catalysts to watch are the next earnings report and gross margin trends.
TWST appears undervalued relative to its own history. The trailing PS ratio of 4.47x is near the bottom of its historical range of 14.2x to 193.3x, indicating the stock is cheap compared to its past. The forward PS of ~1.99x implies the market expects significant revenue growth, which is supported by the 16.9% YoY acceleration. Compared to the medical diagnostics industry, the PS is elevated, but the company's growth rate and leadership in synthetic biology justify a premium. The PEG ratio of 0.34 (based on estimated EPS growth) suggests the stock is undervalued on a growth-adjusted basis. Overall, the valuation is attractive for a high-growth company with improving fundamentals.
TWST is a good buy for growth investors with a high risk tolerance. The company is accelerating revenue growth (16.9% YoY), improving gross margins (52.0%), and has a strong balance sheet (current ratio 3.64). The trailing PS of 4.47x is near the bottom of its historical range, suggesting the stock is undervalued relative to its own past. Analyst consensus is bullish with all 8 analysts rating it Buy/Outperform. However, the stock is unprofitable (net margin -29.4%) and has high volatility (beta 2.115), so it is not suitable for conservative investors. The biggest downside risk is a growth deceleration below 10% or a broad market sell-off, which could drive the stock to $60-$80. For those who can tolerate short-term fluctuations, the risk/reward is favorable at current levels.
TWST is more suitable for long-term investment (3-5 years) given its growth stage and volatility. The company is still unprofitable but has a disruptive platform and accelerating revenue, which could compound over time. The stock's beta of 2.115 makes it highly volatile, so short-term trading carries significant risk of sharp drawdowns. The short ratio of 9.72 days indicates potential for short squeezes, but this is speculative. For long-term investors, the improving fundamentals and low historical PS provide a favorable entry point. A minimum holding period of 3 years is recommended to allow the company to reach profitability and realize its growth potential. Dividend yield is 0%, so the return is entirely dependent on capital appreciation.